Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AiCuris has completed a double-blind randomised placebo controlled dose-finding Phase-II trial to investigate different doses of a new antiviral drug in subjects with genital HSV Type 2 infection and is planning have first data in early 2011.
Subscribe to our email newsletter
AiCuris said that the trial has been completed two months earlier than planned.
Indeed, in the later stages of the trial, enrollment had to be restricted as the number of subjects was higher than the number that was required to be enrolled according to the trial protocol.
AiCuris Clinical Development associate director Burkhard Timmler said that they were surprised by the interest in the trial and the number of requests for participation that they received from people infected with herpes simplex virus.
"In spite of available therapeutic options there seems to be a great demand for a new, well tolerated and efficacious drug for people suffering from genital herpes," Timmler said.
AiCuris CEO Rubsamen-Schaeff said that they hope that the results will allow us to determine the efficacious dose of AIC316 and confirm the potential for once daily oral dosing in genital herpes.